Edition:
United Kingdom

Bellerophon Therapeutics Inc (BLPH.OQ)

BLPH.OQ on NASDAQ Stock Exchange Global Market

2.01USD
21 Feb 2018
Change (% chg)

$-0.01 (-0.50%)
Prev Close
$2.02
Open
$1.98
Day's High
$2.07
Day's Low
$1.98
Volume
16,943
Avg. Vol
51,588
52-wk High
$2.71
52-wk Low
$0.95

Select another date:

Mon, Jan 29 2018

BRIEF-Bellerophon Says Over 100 Patients In Late-Stage Study Testing Inopulse For Treatment Of High Blood Pressure

* BELLEROPHON THERAPEUTICS ANNOUNCES ENROLLMENT EXCEEDS 100 PATIENTS IN PHASE 3 INOVATION-1 STUDY EVALUATING INOPULSE® FOR TREATMENT OF PULMONARY ARTERIAL HYPERTENSION

BRIEF-Bellerophon Says First Patient Enrolled In Phase 2B Study Evaluating Inopulse For Treating Pulmonary Hypertension

* BELLEROPHON-FIRST PATIENT ENROLLED IN PHASE 2B STUDY EVALUATING INOPULSE FOR TREATING PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL LUNG DISEASE

BRIEF-Bellerophon Appoints Ted Wang To Its Board Of Directors

* BELLEROPHON APPOINTS TED WANG, PH.D., OF PUISSANCE CAPITAL MANAGEMENT, TO ITS BOARD OF DIRECTORS

BRIEF-Bellerophon Therapeutics reports Q3 loss per share $0.22

* Bellerophon provides business update and reports third quarter 2017 financial results

BRIEF-Bellerophon Therapeutics says selling stockholders may offer, resell up to 38.9 mln shares - SEC filing

* Bellerophon Therapeutics Inc files to say selling stockholders may offer and resell up to 38.9 million shares of co's common stock - SEC filing

BRIEF-Bellerophon announces $23 million private placement

* Bellerophon Therapeutics Inc - ‍financing was led by Puissance Capital Management and Venrock Healthcare Capital Partners​

BRIEF-Bellerophon announces positive top line Phase 2 data of INOpulse

* Bellerophon announces positive top line Phase 2 data of INOpulse for treatment of Pulmonary Hypertension associated with Chronic Obstructive Pulmonary Disease

Select another date: